CagriSema lower dose results show substantial average weight loss. They don't settle the trade-off against the higher dose used in earlier trials. Counting everyone assigned treatment, loss averaged 19.4% at 1.7 milligrams (mg) of each ingredient and 18.6% at 1.0 mg each. Placebo, an inactive comparison treatment, averaged 4.6%. Some gut symptoms were less frequent at 1.0 mg. Stopping because of health problems wasn't less common.
What the CagriSema lower dose results show
As of November 19, 2026, the day this article was written, the full REDEFINE 9 results are published. Wharton and colleagues' paper appeared online in The Lancet Diabetes & Endocrinology on November 14, alongside Novo Nordisk's announcement.
The trial followed 309 adults with obesity, or overweight plus a related health condition, without diabetes. Treatment lasted 68 weeks, alongside nutrition and physical activity support. People were assigned by chance to either dose or placebo.
CagriSema combines semaglutide, which copies GLP-1, a gut hormone involved in appetite and blood sugar, with cagrilintide. Cagrilintide is an amylin analog, a lab-made version of another fullness hormone. The cagrilintide explainer covers that ingredient.
“1.0 mg each” means 1.0 mg of cagrilintide plus 1.0 mg of semaglutide.
Novo's November 14 release reports two ways of estimating weight loss:
| Average loss at week 68 | 1.7 mg each | 1.0 mg each | Placebo |
|---|---|---|---|
| Counts everyone assigned, including treatment stops or added weight-management treatment | 19.4% | 18.6% | 4.6% |
| Estimates what would happen if everyone continued assigned treatment | 20.7% | 21.0% | 2.0% |
The first row is the treatment-regimen analysis. The second is the efficacy analysis behind the “about 21%” headline. An estimand defines the treatment situation a calculation describes. The second row isn't simply an average of people who finished.
Under that continued-treatment assumption, 95.1% and 96.3% reached at least 5% weight loss, versus 33.4% with placebo. Counting treatment stops, those estimates were 92.8%, 87.7% and 41.1%.
These are combination-drug results. Semaglutide alone is a different treatment, so the percentages do not transfer to a semaglutide prescription.
Did 1.0 mg cause fewer side effects?
Some gut symptoms were numerically less common at 1.0 mg. That didn't translate into fewer people stopping because of health problems.
Adverse events are health problems recorded during a study, whether or not treatment caused them. The paper's abstract reports any such event in 102 of 103 people at 1.7 mg each, 98 of 103 at 1.0 mg each, and 93 of 102 on placebo.
Novo's publication slides, page 14, show the symptom breakdown. The exact treatment-stop rates below come from its November 14 release.
| Reported event | 1.7 mg each | 1.0 mg each | Placebo |
|---|---|---|---|
| Any adverse event | 99% | 95% | 91% |
| Serious health problem | 15% | 13% | 12% |
| Nausea | 66% | 62% | 26% |
| Constipation | 48% | 37% | 21% |
| Diarrhea | 38% | 34% | 25% |
| Vomiting | 32% | 27% | 7% |
| Permanent treatment stop due to adverse events | 2.9% | 4.9% | 4.9% |
Most reported problems were mild or moderate and involved the gut. The table still doesn't establish that 1.0 mg is safer overall.
As of November 19, 2026, the day this article was written, the FDA's November 9 safety communication requires GLP-1 warning changes about possible increased risk of NAION. That's a rare eye-nerve condition that can cause sudden, painless vision loss, including permanent loss. The FDA says to contact a health professional right away for sudden vision loss, blurred or missing areas of vision, color changes or other one-eye vision disturbances. This small trial cannot settle rare risks or show that lower doses reduce them.
What changes for semaglutide or tirzepatide?
The finding adds evidence about dose flexibility for a medicine still being developed. It doesn't establish a new dose plan for someone taking semaglutide or tirzepatide.
REDEFINE 9 compared CagriSema with placebo. It had no semaglutide-only or tirzepatide group. The CagriSema versus tirzepatide comparison covers the separate studies behind that question.
For a current prescription, the prescriber sets the actual dose, weighing response, side effects and medical history. Similar-looking percentages from different studies cannot choose between medicines for an individual.
Does this mean lower doses equal the full dose?
That remains unproved. REDEFINE 9 had no group receiving 2.4 mg of each ingredient, the higher dose used in earlier studies.
It also wasn't powered, meaning sized and statistically planned, to detect differences between its two active doses. Each dose was tested against placebo. The close averages don't establish that 1.0 mg and 1.7 mg work equally well.
Nor do these results establish the smallest effective dose or what happens after treatment ends. Novo funded the trial.
What the early-responder analysis adds
As of November 19, 2026, the day this article was written, Novo's November 15 release adds a separate look at early response. It revisits REDEFINE 1, published in the New England Journal of Medicine in 2025, which studied 2.4 mg of each ingredient.
The conference poster reports that about two in three participants in this analysis, 67.8%, lost at least 5% by week eight. Observed weight loss at week 68 was 25.4% among early responders and 17.8% among delayed responders, those below that mark at week eight.
This was post hoc: researchers looked back at existing data to ask another question. The figures describe measurements while people were taking treatment. They aren't a week-eight stopping rule, and they don't describe the lower-dose trial. Delayed response didn't mean no later response.
What this means for a prescription
CagriSema is Novo's investigational combination, meaning it is still being studied. Compounded semaglutide, prepared by a pharmacy for a prescription, is a different treatment.
Semaglutide and tirzepatide prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy as compounded medications, which are different from FDA-approved products: the formulations offered here are not FDA-approved. As of November 19, 2026, the day this article was written, the FDA's compounding explanation carries ‘Content current as of: 06/22/2026.’ The agency doesn't review compounded preparations for safety, effectiveness or quality before marketing.
A licensed provider may still prescribe — that decision is between you and your doctor.
At Promise, a licensed U.S. provider reviews every request, and not everyone qualifies.
What to watch next
As of November 19, 2026, the day this article was written, CagriSema remains investigational and is not FDA-approved. The FDA's 2026 new-drug list, current November 19, lists neither CagriSema nor cagrilintide. Novo's November 14 release says it filed the 2.4 mg/2.4 mg application in December 2025 and expects a decision in the fourth quarter of 2026. An expected window doesn't guarantee a decision or launch date.
The useful next evidence would directly compare doses and follow people longer. Separate questions about menopause and food noise have their own studies; this trial doesn't answer them.





